Sharemaestro Newsreel

Pfizer site developer’s complex conversion technique draws attention after collapse scare

Nathan Berman's complex conversion technique at a former Pfizer site has come under scrutiny after a collapse scare. Falling debris from a 37-story Midtown Manhattan building undergoing office-to-residential conversion led to building evacuations and street closures. The incident draws attention to the challenging engineering …

Pfizer Inc. (PFE) Stock Analysis: Evaluating a 14.92% Potential Upside Amidst Strong Dividend Yield

This article analyzes Pfizer Inc. (PFE), highlighting its potential 14.92% upside and strong 6.87% dividend yield. While performance metrics and strategic collaborations suggest growth, the high 131.30% payout ratio raises questions about dividend sustainability. Analyst sentiment is mixed, indicating cautious optimism, while technical indicators …

Novo Nordisk launches cheaper Ozempic in South Africa

Novo Nordisk has introduced a lower-cost version of its weight-loss drug, Ozempic, in South Africa, aiming to combat counterfeit products. This move follows a court victory against local pharmacies making unauthorized copies. South Africa has the highest adult obesity rate in Africa, and the …

Why Johnson & Johnson Is a Stock You Can Own Forever

Johnson & Johnson (JNJ) is presented as a stock ideal for long-term investors due to its strong balance sheet, 64-year dividend growth streak, and diversified healthcare business spanning pharmaceuticals and medical devices. The company's durability is evidenced by its consistent revenue growth across six …

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is actively developing several weight management drugs and recently acquired Metsera, significantly boosting its pipeline in this growing market. While Pfizer has promising candidates, particularly MET-097i with potential for monthly dosing, it faces strong competition from market leaders like Eli Lilly and Novo …

Boston Common Asset Management LLC Lowers Stake in Amgen Inc. $AMGN

Boston Common Asset Management LLC decreased its stake in Amgen Inc. by 10.4% in the first quarter, selling 3,458 shares and leaving its holding valued at $10.4 million. Despite this, Amgen reported strong first-quarter results, beating EPS and revenue estimates, and raised its FY …

AlTi Global Inc. Cuts Stock Position in Amgen Inc. $AMGN

AlTi Global Inc. significantly reduced its stake in Amgen Inc. by 31.7% in the first quarter, selling 9,833 shares and valuing its remaining 21,159 shares at $7.445 million. While institutional investors collectively own 76.50% of Amgen, several other hedge funds either increased or decreased …

Novartis pipeline faces critical test as upcoming trial results underpin growth outlook

Novartis is facing a critical period as upcoming trial results for three late-stage medicines will determine its long-term growth. These trials for pelacarsen, remibrutinib, and del-desiran are crucial for supporting the company's premium market valuation and offsetting future patent expirations, with analysts projecting these …

What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

FY2026 EPS Estimates for Amgen Lowered by Erste Group Bank

Erste Group Bank has slightly lowered its FY2026 EPS estimate for Amgen to $22.41, maintaining a Hold rating, although this updated estimate remains above the broader consensus. Amgen recently exceeded first-quarter expectations with strong EPS and revenue, and reaffirmed its FY2026 guidance. Analyst sentiment …

Novartis Drug Pipeline Faces Test Amid Valuation Premium Concerns

Novartis's premium valuation depends heavily on the upcoming trial results for three key experimental drugs: pelacarsen, remibrutinib, and del-desiran. These drugs are crucial for offsetting an anticipated $4 billion loss from generic competition, particularly for Entresto. Analysts suggest that at least two of these …

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, …

Lobbying Update: $60,000 of PFIZER lobbying was just disclosed

A recent Lobbying Disclosure Act filing revealed that Pfizer (PFE) disclosed $60,000 in lobbying expenditures for Q2 2026. The lobbying efforts focused on issues including drug development and pricing, vaccine safety and access, the 340B program, and pharmacy benefit managers. The article also provides …

Organon stock trades steady as women’s health focus meets mixed earnings momentum

Organon stock demonstrates a balance between its specialized women's health portfolio and its recent financial performance. The company, which separated from Merck, reported $6.26 billion in revenue and $586 million in net income for 2023, while managing its debt and maintaining a $0.28 quarterly …

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The European Commission approved Novo Nordisk A/S' Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related …

Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged

Pfizer (NYSE:PFE) shares rose 3.6% last week, outperforming the S&P 500, primarily due to the appeal of its 6.9% dividend yield rather than an increase in earnings forecasts. Analyst expectations for 2026 earnings actually saw a slight decrease. The company also saw a new …

Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention

The article argues that the Enanta v. Pfizer case is not merely about a typographical error in a patent application, but rather about whether the inventors possessed the invention prior to Pfizer's public disclosure of nirmatrelvir. It claims the Federal Circuit applied the wrong …

Earnings To Watch: Novartis AG (XSWX:NOVN) Reports Q2 2026 Result

Novartis AG (XSWX:NOVN) is scheduled to release its Q2 2026 earnings on July 21, 2026, with an estimated revenue of $11.34 billion and earnings of $1.40 per share. While full-year 2026 estimates for revenue and earnings have slightly declined, 2027 estimates show an increase. …

Grifols stock steadies on 2025 revenue and debt metrics

Grifols' stock performance is currently being evaluated by investors based on its 2025 financial results, which include €7.64 billion in revenue, €1.63 billion in adjusted EBITDA, and a net debt of €8.8 billion. These figures establish a crucial baseline for assessing the company's profitability, …

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital are establishing a new biopharmaceutical company focused on developing therapies for autoimmune diseases. The venture will be launched with $300 million in financing, primarily led by Bain Capital and including funds from the Canada Pension Plan Investment Board. …

Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma

Bristol Myers Squibb's stock (BMY) rose 5.5% after the FDA accepted its New Drug Application for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, supported by positive Phase 3 data. This development is crucial for BMS as it aims to strengthen its …

Swiss National Bank Buys 105,080 Shares of Amgen Inc. $AMGN

The Swiss National Bank increased its stake in Amgen Inc. by 7.1% in the first quarter, purchasing an additional 105,080 shares and bringing its total holdings to over 1.58 million shares valued at $556 million. Other hedge funds also adjusted their positions in Amgen, …

SEB Asset Management AB Purchases New Position in Amgen Inc. $AMGN

SEB Asset Management AB has acquired a new position in Amgen Inc., purchasing 180,676 shares valued at approximately $63.6 million during the first quarter. Amgen's latest earnings surpassed expectations with an EPS of $5.15 and revenue of $8.62 billion, a 5.8% year-over-year increase. Despite …

Mediolanum International Funds Ltd Buys 7,075 Shares of Amgen Inc. $AMGN

Mediolanum International Funds Ltd increased its stake in Amgen Inc. by 7.9% in the first quarter, purchasing 7,075 additional shares to hold a total of 96,663 shares valued at approximately $33.7 million. Amgen reported strong Q1 results, exceeding analyst expectations with EPS of $5.15 …

Valley Wealth Managers Inc. Reduces Stock Position in Amgen Inc. $AMGN

Valley Wealth Managers Inc. decreased its stake in Amgen Inc. by 18.7% in the first quarter, selling 15,907 shares and now holding 69,051 shares valued at approximately $24.3 million. Despite mixed analyst sentiment with a consensus "Hold" rating and a target price of $356.62, …

Devika Gupta Joins Sanofi as Head of Value for Healthcare Systems & Economics

Sanofi has appointed Devika Gupta as Head of Value for Healthcare Systems & Economics to bolster its market access, pricing, and value-based healthcare strategies globally. Gupta brings over 25 years of experience from previous leadership roles at Merck, Pfizer, Campbell Alliance, Johnson & Johnson …

5,891 Shares in Amgen Inc. $AMGN Bought by Independent Financial Group LLC

Independent Financial Group LLC has acquired a new stake in Amgen Inc., purchasing 5,891 shares valued at approximately $2.07 million during the first quarter. Amgen reported strong Q1 earnings, beating expectations with an EPS of $5.15 and revenue of $8.62 billion, a 5.8% increase …

Amgen (AMGN) RBC Capital Markets Global Healthcare Conference 2025 Summary

Amgen reported strong Q1 2025 results with a 9% revenue increase and 24% non-GAAP EPS growth, driven by key products like Repatha and Evenity, and a robust biosimilars portfolio. The company highlighted significant pipeline advancements, including late-stage trials for Olpacerin and Maritide, and expanded …

AIA Group Ltd Grows Stake in Amgen Inc. $AMGN

AIA Group Ltd increased its stake in Amgen Inc. by 11.2% in the first quarter, bringing its total holdings to 27,962 shares valued at $9.84 million. Other institutional investors also adjusted their positions in Amgen. The stock currently has an average rating of "Hold" …

AstraZeneca needs a shot in the arm to hit $80bn revenue target

Amarin Corporation (AMRN) EVP reports RSU vesting and ADS tax withholding

Amarin Corporation's EVP and Chief Scientific Officer, Steven B. Ketchum, reported recent equity activity. On July 1, 2026, he acquired 3,688 American Depositary Shares (ADS) from restricted stock unit vesting, while 1,887 ADS were withheld to cover tax obligations. Following these transactions, Ketchum directly …

Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension …

Avoiding Lag: Real-Time Signals in (GSK) Movement

This article provides real-time signal analysis for GSK, highlighting weak near-term sentiment but strong long-term projections. It offers three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels …

Merck stock holds steady as Keytruda drives revenue growth and investors watch oncology momentum

Merck & Co. (MRK) stock remains strong, driven primarily by the blockbuster cancer drug Keytruda and its robust vaccine portfolio, which collectively fueled approximately 15.6% revenue growth to $60.1 billion in 2023. Keytruda alone accounted for over $25 billion in sales, solidifying its position …

Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease

Sanofi's oral TREM2 agonist, SAR448851, is progressing to a Phase 2 clinical trial named TREMHANCE for early Alzheimer's disease. The trial will evaluate the drug's efficacy and safety, with the primary endpoint being the change in plasma p-tau217 at week 48, aiming to shift …

Amarin to release Q2 results before July 29 conference call

Amarin (NASDAQ: AMRN) announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before market open. This will be followed by a conference call with senior management at 8:00 a.m. ET. Investors can access the live call via telephone …